Despite significant advances in the understanding, prevention, diagnosis and treatment of pancreatic cancer, it continues to affect millions of people around the world. People with diabetes have an increased lifetime risk of developing pancreatic cancer. Sodium-glucose co-transporter 2 (SGLT2) inhibitors and metformin are drugs widely used to treat type 2 diabetes, and both have been associated with a reduction in the risk of pancreatic cancer.
